Relation between respiratory symptoms, pulmonary function and peak flow variability in adults

H M Boezen, J P Schouten, D S Postma, B Rijcken

Abstract

Background – A study was carried out to determine whether subjects with respiratory symptoms are more likely to have impaired lung function or increased airway lability, and to quantify these relationships in a population of adults.

Methods – Data were collected from 511 participants (aged 20–70 years) from the Dutch part of the European Community Respiratory Health Survey (ECCHS). The symptoms analysed were: wheeze, dyspnoea $\geq$ grade 3, nocturnal dyspnoea, cough and phlegm, and history of allergy. Lung function was measured by peak expiratory flow (PEF) and forced expiratory volume in one second (FEV$_1$). PEF variability was used as an index for bronchial lability.

Results – Both FEV$_1$ and PEF were decreased in subjects with increasing numbers of symptoms. Subjects with one symptom had an increased risk of having an FEV$_1$ value of $<70\%$ (OR = 4.2) and this risk increased with an increasing number of symptoms. Subjects with three or more symptoms had an increased risk of having a PEF value of $<70\%$, a diurnal variation in PEF of $>10\%$ (both OR = 4.4), and an increased risk of high between day variation (OR = 6.6).

Conclusions – Subject-reported symptoms are related to impaired lung function and to increased variability of peak flow.

(Thorax 1995;50:121–126)

Keywords: pulmonary function, respiratory symptoms, peak expiratory flow.

A considerable proportion of the adult population in western society is affected by chronic obstructive lung disease. Depending on the definition, 5–10% of younger adults (20–45 years of age) suffer from mild to severe asthma. In older age groups symptoms such as chronic expectoration are common. In the elderly prevalence rates are high$^{1,2}$ and increase with age. In several population studies of subjects above 60 years 30–60% reported one or more chronic respiratory symptoms such as chronic cough or phlegm, dyspnoea, persistent wheeze, or chest tightness. Spirometric tests often reveal severe impairment of lung function and the clinical prognosis, in terms of mortality risk, is unfavourable for these subjects.$^{3,4}$

Symptoms are generally the primary reason for consultation with a doctor. The general practitioner will restrict diagnostic activities to a medical history and examination. In most cases spirometric tests will not be performed. Chronic respiratory symptoms are associated with diminished lung function and increased airway lability.$^{5,7}$ Once lung function impairment has been quantified by measurement of the FEV$_1$ or PEF variability, any further changes – such as decline in lung function or improvement as a result of interventions – can be monitored. Although simple lung function equipment is becoming increasingly available, it remains uncertain for which cases spirometric testing is useful. The same is true for the assessment of airway lability by repeated peak flow measurements at home.

We studied a random sample of adults in a wide age range (20–70), collecting information on respiratory symptoms, spirometric parameters, and peak flow measurements. The aim of the study was to investigate whether subjects with respiratory symptoms are more likely to have impaired lung function or increased airway lability, and whether this association is stronger in older subjects.

Methods

Data collection and analyses

In the city of Groningen, The Netherlands, an age stratified random sample of 750 men and 750 women aged 20–70 were invited to participate in a respiratory survey. Data on respiratory symptoms and smoking habits were collected by means of the standardised questionnaire of the ECCHS.$^3$ Symptoms were defined as: (1) wheezing or whistling without having a cold at any time in the last 12 months (wheeze); (2) shortness of breath when walking with other people of their own age on level ground (dyspnoea $\geq$ grade 3); (3) woken up by an attack of shortness of breath at any time in the last 12 months (nocturnal dyspnoea); (4) cough, usually first thing in the morning, during the day or at night in the winter (cough); (5) phlegm, usually first thing in the morning, during the day or at night in the winter (phlegm); (6) presence of a runny or stuffy nose or itchy watering eyes, cough, wheeze or sneeze, tightness in the chest, or shortness of breath when near animals or trees, grass, flowers or with increased levels of pollen (history of allergy). Subjects who denied having any of these symptoms were considered to be asymptomatic and were further described as the “no symptom” group. The cumulative amount of cigarettes ever smoked was cal-
culated and expressed in pack-years (1 pack-year = 25 cigarettes per day for one year).

Participants were given a mini-Wright peak flow meter (Clement Clarke International Ltd, London, UK) and were instructed in its use by a trained technician. Participants performed PEF measurements at home every morning on rising and again every afternoon between 5.00 pm and 6.00 pm, before dinner, for seven successive days. The highest values of the morning and the afternoon were used in the analyses. If subjects were receiving bronchodilator treatment PEF values had to be measured before its use. Every peak flow meter was checked by a trained technician before distribution and upon return.

PEF variability was expressed in two ways: (1) diurnal PEF variation (amplitude % mean) defined as: (highest PEF − lowest PEF)/(mean value of the two) × 100% over a minimum of five days; and (2) between day PEF variation defined as: standard deviation of a minimum of five mornings as a percentage of the mean morning PEF (SD% mean morning PEF).

The FEV₁ was measured using the ECRHS lung function protocol that meets the American Thoracic Society guidelines. Measurements were performed with a dry seal Morgan Spiroflow Ds12 (PK Morgan Ltd, UK). Age and height were centred to the mean (mc). To describe the dependencies of FEV₁ and PEF on age and height in this population several models were investigated, especially with regard to the age variable (entered into the model as, for example, age or as the reciprocal of age). The linear model fitted the best (65% explained variance). Prediction equations were based on this linear model. The predicted (pred) FEV₁ and PEF for this population were:

\[
\text{FEV}_1 \text{ pred men} = (4.33 + 4.46 × \text{mc height} - 0.033 × \text{mc age}) \times \text{RSD} = 0.5815
\]

\[
\text{FEV}_1 \text{ pred women} = (3.18 + 3.57 × \text{mc height} - 0.024 × \text{mc age}) \times \text{RSD} = 0.38
\]

\[
\text{PEF pred men} = (600 + 429 × \text{mc height} - 1.571 × \text{mc age}) \times \text{RSD} = 0.769
\]

\[
\text{PEF pred women} = (446 + 140 × \text{mc height} - 2.152 × \text{mc age}) \times \text{RSD} = 0.608
\]

FEV₁ and morning PEF values were expressed as percentage of predicted values, a value of less than 70% predicted being considered abnormal. Values below these limits were defined as "low FEV₁" and "low morning PEF" respectively. Odds ratios for "low FEV₁" and "low PEF" were estimated according to the number of respiratory symptoms (logistic regressions with adjustment for gender, age, height, pack-years). Odds ratios were considered significant if the 95% confidence interval did not include the value 1.

Diurnal variation in PEF of more than 10% was considered to be abnormal. Above this limit diurnal variation in PEF was defined as "high diurnal PEF variation". Between day variation in PEF above 8% (95th percentile) was considered to be abnormal and defined as "high between day PEF variation". Logistic regression was performed to estimate the odds ratios on either of these two forms of high PEF variability depending on the number of respiratory symptoms (with adjustment for gender, age, height, and pack-years).

Distributions of FEV₁, PEF or PEF variability were inspected visually by normal probability plots of the standardised residuals of the total population and tested formally by the Kolmogorov-Smirnov test. Parametric tests were used to analyse normal distributions and, for skewed distributions, log transformations were performed to achieve normalisation. Analyses were performed on these log transformed data. Means were transformed back to normal units (geometric means) unless otherwise stated. Differences between means were tested using t tests or analyses of covariance by multiple regression method (ANCOVA). Differences between proportions were tested using \( \chi^2 \) tests. All tests were two sided and p values of <0.05 were considered significant. To investigate the association of symptoms with lung

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Respiratory symptoms stratified by sex and age</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Men</strong></td>
<td><strong>Women</strong></td>
</tr>
<tr>
<td>20–44 years</td>
<td>45–69 years</td>
</tr>
<tr>
<td>(n = 124 (46.8%))</td>
<td>(n = 141 (53.2%))</td>
</tr>
<tr>
<td>Wheeze</td>
<td>14 (10.3)</td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>9 (7.3)**</td>
</tr>
<tr>
<td>Nocturnal dyspnoea</td>
<td>3 (2.4)</td>
</tr>
<tr>
<td>Cough</td>
<td>4 (3.2)</td>
</tr>
<tr>
<td>Pfslegm</td>
<td>3 (2.4)</td>
</tr>
<tr>
<td>History of allergy*</td>
<td>42 (33.9)</td>
</tr>
<tr>
<td>0 symptom</td>
<td>71 (57.3)</td>
</tr>
<tr>
<td>1 symptom</td>
<td>78 (60.9)</td>
</tr>
<tr>
<td>2 symptoms</td>
<td>9 (7.3)</td>
</tr>
<tr>
<td>&gt; 3 symptoms</td>
<td>7 (5.6)</td>
</tr>
</tbody>
</table>

* Significant difference between men and women; ** significant differences between age groups by sex (\( \chi^2 \) tests, p < 0.05).
function and age, stepwise multiple regression analyses were performed including interaction terms of the separate symptoms with age. All analyses were performed with the SPSS/PC+V4.0 package. This study was part of the European Community Respiratory Health Survey, a multicentre study on respiratory health.

Results

Of the 1500 subjects who were invited to participate in the ECRHS, 836 (56%) responded. Responders were more likely to be older and to have symptoms than non-responders, but these differences were small and not significant. PEF measurements were made in a group randomly chosen from these responders. Of the 579 subjects who were randomly asked to join the current study 573 (99%) agreed to participate. All had performed lung function testing and completed the questionnaire. A completely filled in and readable PEF recording form was received from 520 subjects (90.8%) and their data were analysed. The group who failed to return a properly filled in form (n = 53) did not differ from the analysed group in age and sex distributions, but contained relatively more current smokers and less never smokers (χ² test, p<0.001). As the mean PEF values of the study population on the first day were significantly lower than on the other days, the data from day 1 were excluded from the analyses. After this exclusion, nine subjects had less than the required five days and their data were not analysed. Data of 511 subjects (265 men and 246 women aged 20–70) were used for the analyses. The population characteristics are shown in table 1. Detailed data on the distributions of PEF flow have been described elsewhere. Approximately 50% of the total study population reported one or more of the following symptoms (table 2): wheeze, dyspnoea ≥ grade 3, nocturnal dyspnoea, cough or phlegm, allergic symptoms. One symptom was reported by 30%, two symptoms were reported by 10%, and three or more symptoms by approximately 8% of the subjects. Women reported slightly more respiratory symptoms than men. The frequency of the respiratory symptoms is shown in table 2, stratified by age and sex.

Mean FEV₁, % predicted was significantly different in the various symptom groups (fig 1), being highest in the "no symptom" group and lowest in those who reported ≥ 3 symptoms (p<0.001 adjusted for sex, age, height, and pack-years). Similar significant differences between symptom groups were found for PEF % predicted (fig 2) (p<0.0001 adjusted for sex, age, height, and pack-years).

There was a positive association between the number of symptoms and the magnitude of the diurnal PEF variation, with the highest mean variation in subjects reporting ≥ 3 symptoms and the lowest mean variation in the "no symptom" group (fig 3) (p<0.001 adjusted for sex, age, height, and pack-years). The same positive association was found between the number of reported symptoms and the between day variation in PEF (fig 4).
Diurnal and between day variation in PEF were both associated with age (with greater values at older ages), pack-years, and sex (table 3). To quantify the association of the separate respiratory symptoms with PEF variability and FEV₁, and PEF, multiple regressions were performed with simultaneous adjustments for age, height, sex, pack-years, and each of the other symptoms (table 3). Subjects reporting wheeze had significantly lower FEV₁ than subjects without this symptom ($\beta = -0.18$; $p<0.01$). Nocturnal dyspnoea was associated with significantly higher diurnal and between day variation in PEF, and lower PEF and FEV₁ ($p<0.01$) (table 3). Cough was associated with higher diurnal and between day variation in PEF ($\beta = 0.20$ and $\beta = 0.13$ respectively; $p<0.05$) and a lower morning PEF ($\beta = -48.34$; $p<0.005$). Dyspnoea ≥ grade 3 had a significant negative association with the FEV₁ ($\beta = -0.13$; $p<0.05$). Phlegm and history of allergy were neither significantly associated with PEF variability, nor with PEF or FEV₁ (table 3).

To estimate the odds ratios for “low PEF”, “low FEV₁”, “high diurnal PEF variation”, and “high between day PEF variation” in association with the number of respiratory symptoms logistic regressions were performed (table 4). Subjects who reported having three or more symptoms had greater odds for low morning PEF (OR = 4.4), low FEV₁ (OR = 7.6), high diurnal PEF variation (OR = 4.4), and high between day PEF variation (OR = 6.6) than those with no symptoms (table 4). The odds ratio for low FEV₁ was at least four times greater in subjects with any symptom than in those without symptoms.

Age modified the association between nocturnal dyspnoea and between day variation in PEF ($\beta = 0.002$, $p<0.005$). Older age groups with nocturnal dyspnoea thus had a greater variation in PEF between days than might be expected based on age, height, sex, and pack-years. Adjustment for initial PEF did not change this significant interaction. The PEF had a significant negative interaction with the presence of cough and age ($\beta = -1.34$, $p<0.001$). Thus, in older patients cough was associated with lower PEF values than might have been expected on the basis of age, height, sex, and pack-years. This interaction term remained significant after adjustment for initial PEF.

### Discussion

These results show that approximately 50% of a random population of adults reported one or more respiratory symptoms. Older people tended to report symptoms more often and the proportion of subjects with two or more symptoms increased with age. On average, subjects with wheeze, dyspnoea ≥ grade 3, and nocturnal dyspnoea had significantly lower levels of FEV₁ (% predicted). Subjects with nocturnal dyspnoea and cough had significantly lower levels of PEF (% predicted). With increasing numbers of symptoms the mean levels of FEV₁ and PEF were lower. On average, subjects with two or more symptoms had a seven times greater risk of significant impairment of FEV₁ (<70% predicted). Subjects with three or more symptoms had a four times higher risk of a PEF of <70% predicted and a high diurnal PEF variation (>10%) than

### Table 3

Regression coefficients $\beta$ (with standard error (SE) and $p$ values) resulting from multiple regression analyses with respiratory symptoms as independent variables and FEV₁, morning PEF, diurnal PEF variation and between day PEF variation respectively, as dependent variables, adjusted for pack-years, sex, mean centred age, mean centred height, and other respiratory symptoms.

<table>
<thead>
<tr>
<th>Variable</th>
<th>FEV₁ (l)</th>
<th>PEF (l/min)</th>
<th>Diurnal PEF variation†</th>
<th>Between day PEF variation†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$\beta$</td>
<td>SE</td>
<td>$p$</td>
<td>$\beta$</td>
</tr>
<tr>
<td>Wheeze</td>
<td>-0.18</td>
<td>0.07</td>
<td>0.01</td>
<td>-15.02</td>
</tr>
<tr>
<td>Dyneopoea ≥ grade 3</td>
<td>-0.13</td>
<td>0.07</td>
<td>&lt;0.05</td>
<td>-2.65</td>
</tr>
<tr>
<td>Nocturnal dyspnoea</td>
<td>-0.36</td>
<td>0.11</td>
<td>0.00</td>
<td>-43.48</td>
</tr>
<tr>
<td>Cough</td>
<td>-0.07</td>
<td>0.11</td>
<td>NS</td>
<td>-48.34</td>
</tr>
<tr>
<td>Age</td>
<td>0.20</td>
<td>0-11</td>
<td>NS</td>
<td>20.54</td>
</tr>
<tr>
<td>Height</td>
<td>0.72</td>
<td>0-35</td>
<td>NS</td>
<td>331.0</td>
</tr>
<tr>
<td>Sex (F:M)</td>
<td>-1.14</td>
<td>0-05</td>
<td>0-00</td>
<td>-154.5</td>
</tr>
<tr>
<td>Pack-years</td>
<td>-0.01</td>
<td>0-00</td>
<td>0.00</td>
<td>-1-20</td>
</tr>
<tr>
<td>Intercept</td>
<td>6.07</td>
<td>0-16</td>
<td>0-00</td>
<td>864.3</td>
</tr>
<tr>
<td>RSD</td>
<td>0.49</td>
<td>0-71</td>
<td>0-00</td>
<td>71-0</td>
</tr>
</tbody>
</table>

RSD = residual standard deviation. † Analyses have been performed on the log transformed values of diurnal PEF variation and between day PEF variation.

### Table 4

Odds ratios (OR) estimated from logistic regression with FEV₁ <70% predicted, morning PEF <70% predicted, morning PEF, diurnal PEF variation <10% and between day PEF variation >8% as dependent variables and the number of respiratory symptoms compared with no respiratory symptoms, mean centred age, mean centred height, pack-years, and sex as independent variables.

<table>
<thead>
<tr>
<th>Variable</th>
<th>n</th>
<th>FEV₁ &lt;70% predicted</th>
<th>Morning PEF &lt;70% predicted</th>
<th>Diurnal PEF variation &gt;10%</th>
<th>Between day PEF variation &gt;8%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR</td>
<td>95% CI</td>
<td>OR</td>
<td>95% CI</td>
<td>OR</td>
</tr>
<tr>
<td>1 symptom</td>
<td>156</td>
<td>4.2 1-1 to 16-6</td>
<td>1-4 0-4 to 4-6</td>
<td>1.0 0-1 to 3-0</td>
<td>1-4 0-4 to 4-4</td>
</tr>
<tr>
<td>2 symptoms</td>
<td>200</td>
<td>9.0 1-8 to 43-7</td>
<td>2.7 0-9 to 10-6</td>
<td>1-8 0-5 to 6-2</td>
<td>2-5 0-6 to 10-7</td>
</tr>
<tr>
<td>≥ 3 symptoms</td>
<td>39</td>
<td>7-6 1-1 to 52-8</td>
<td>4-4 1-1 to 18-6</td>
<td>4-4 1-2 to 16-0</td>
<td>6-6 1-9 to 22-5</td>
</tr>
</tbody>
</table>

FEV₁ = forced expiratory volume in one second; PEF = peak expiratory flow.
asymptomatic subjects. The risk of a high variation in between day PEF (>8%) increased by six times in subjects with three or more symptoms. Airway lability intensified with increasing age and with higher numbers of reported symptoms, and appeared to be significantly greater in subjects with nocturnal dyspnoea and cough.

Several studies have investigated the predictive value of respiratory symptoms for (annual) change in FEV₁ in children16-19 or adults.20,21 Jaakkola and coworkers followed a population of young adults for a period of eight years and found larger negative annual changes in FEV₁ in subjects who reported new onset of wheeze or dyspnoea.20 Another longitudinal population study performed by Sherman and coworkers reported an accelerated loss in FEV₁ in men with cough and phlegm and women with cough alone.21 Krzyzanowski and coworkers described lower levels of FEV₁ if the symptoms “attacks of breathlessness” and “exertional dyspnoea” (“dyspnoea ≥ grade 3”) were present, independent of other respiratory symptoms. Like Krzyzanowski, we found significantly lower values for FEV₁ when dyspnoea ≥ grade 3 was present, but also when wheeze or nocturnal dyspnoea were reported. Besides the association of nocturnal dyspnoea with a lower level of FEV₁, we found this symptom to be associated with a lower PEF and higher diurnal and between day variation in PEF. Brand and coworkers reported the same association with higher values of diurnal PEF variation in a group of patients with respiratory diseases, specifically in those patients with asthmatic bronchitis and asthma.

No significant association was found between diurnal variation in PEF and phlegm. This finding is in accordance with results presented by Neukirch and coworkers.23 In contrast to Neukirch, we did find a positive association between the presence of cough and the magnitude of the diurnal variation in PEF. This difference in results may be explained by the fact that our population consisted of a random sample of adults in a wider age range than the French study which consisted of younger individuals.

After adjustment for other respiratory symptoms, history of allergy was not associated with either airway lability or lung function. Nevertheless, we did not exclude history of allergy from the analyses because it is an often reported, well recognised, and specific symptom. In addition, the amount of explained variation in PEF, FEV₁, and PEF variability was increased when history of allergy was included in the model. A history of allergy therefore appears to have additional predictive value in the presence of other symptoms.

This study was performed to determine whether the presence of respiratory symptoms was associated with impairment of lung function. The symptoms we asked for were prevalent in this study population. More than any specific symptom, the presence of several symptoms appeared to be strongly associated with significant impairment of lung function. This association did not change when those subjects with doctor diagnosed asthma (n = 39) were excluded.

Significant impairment of lung function was defined as an FEV₁ of <70% predicted. As the dependency of lung function on age is curvilinear, this may result in an overestimation of the proportion of older subjects with an FEV₁ of <70% predicted. However, we investigated several models in relation to the age variable and found that the linear model fitted the best. For the current population an FEV₁ of <70% therefore seems to be a legitimate definition of significant impairment of lung function for the whole group.

One cannot be sure of the underlying process responsible for the altered relationship between nocturnal dyspnoea and cough, on the one hand, and lung function in the older subjects on the other. It is possible that cardiac disease, which frequently occurs with increasing age, affects this relationship. However, the results did not change when the variable “use of heart medication” was included in the analyses, nor when the subjects who reported the use of heart medication were excluded from the analyses. This does not permit conclusions, however, as we did not perform clinical diagnostic measurements to quantify cardiac disease when subjects reported use of heart medication. Further studies on the effects of comorbidity on lung function with increasing age are required.

Because the current analyses were performed on data collected in a cross-sectional study, no conclusions can be drawn on whether respiratory symptoms preceded or were a result of lower FEV₁ or PEF or increased airway lability.

This study shows that an increasing number of symptoms occur with increasing age. A higher risk of significant impairment of FEV₁ is present for subjects with two symptoms or more. General practitioners should therefore ask subjects about symptoms such as nocturnal dyspnoea and cough when any respiratory symptom is mentioned, especially if subjects are elderly. As adaptation to respiratory symptoms in elderly subjects appears to be common, general practitioners should be particularly alert to every patient who reports such symptoms when attending his or her practice. The presence of more than one respiratory symptom in elderly patients should alert the practitioner to the possibility of chronic impairment of lung function.

This study was supported by grants from the Ministry of Wellbeing, Public Health and Culture, The Netherlands, Jan Kornelis de Cock Foundation, Groningen, The Netherlands, and the Netherlands Asthma Fund, Grant Number 92-12. Glaxo Pharmaceuticals kindly provided the peak flow meters.

5 Hangreave FE, Ryan G, Thomson NC, O’Byrne PM, La-
126

Boezen, Schouten, Postma, Rijcken

Relation between respiratory symptoms, pulmonary function and peak flow variability in adults.
H M Boezen, J P Schouten, D S Postma and B Rijcken

Thorax 1995 50: 121-126
doi: 10.1136/thx.50.2.121

Updated information and services can be found at:
http://thorax.bmj.com/content/50/2/121

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/